Journal article
A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment
Arabella Young, Shin Foong Ngiow, Yulong Gao, Ann-Marie Patch, Deborah S Barkauskas, Meriem Messaoudene, Gene Lin, Jerome D Coudert, Kimberley A Stannard, Laurence Zitvogel, Mariapia A Degli-Esposti, Eric Vivier, Nicola Waddell, Joel Linden, Nicholas D Huntington, Fernando Souza-Fonseca-Guimaraes, Mark J Smyth
Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2018
Grants
Awarded by National Health and Medical Research Council of Australia (NHMRC)
Awarded by Susan G. Komen Program
Awarded by National Institutes of Health
Awarded by NHMRC C.J. Martin Fellowship
Awarded by NHMRC Early Career Fellowship
Awarded by National Breast Cancer Foundation (NBCF) Fellowship
Awarded by Priority-driven Collaborative Cancer Research Scheme
Funding Acknowledgements
The authors wish to thank Stefano Mangiola, Marit Inngjerdingen, Ludovic Martinet, Dipti Vijayan, and Stephen Blake for their helpful discussions and critical review of the manuscript. We thank Yuan Ji Day (Chang Gung University, Tauyuan, Taiwan) for creating the A2AR floxed mice. We also thank Liam Town and Kate Elder for maintaining the mice used in this study and the QIMR Berghofer animal facility and flow cytometry facilities for their assistance. A. Young was supported by a Cancer Council Queensland Ph.D. fellowship. M.J. Smyth was supported by a National Health and Medical Research Council of Australia (NHMRC) Senior Research Fellowship (1078671) and Project Grant (1120887), a Susan G. Komen Program Grant (IIR12221504), and a Cancer Research Institute Clinical Strategy Team Grant. J. Linden was supported by a grant from the National Institutes of Health (R01 HL111969). S.F. Ngiow was supported by an NHMRC C.J. Martin Fellowship (1111469). F.S.F. Guimaraes was supported by a NHMRC Early Career Fellowship (1088703), a National Breast Cancer Foundation (NBCF) Fellowship (PF-15-008), and grant # 1120725 awarded through the Priority-driven Collaborative Cancer Research Scheme and funded by Cure Cancer Australia with the assistance of Cancer Australia. N.D. Huntington is a recipient of a NH&MRC Project Grant, Melanoma Research Grant from the Harry J Lloyd Charitable Trust, and a Cancer Research Institute Clinical and Laboratory Integration Program (CLIP) grant.